[1] |
World Health Organization. Global tuberculosis report 2020. Geneva: World Health Organization, 2021.
|
[2] |
World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization, 2019.
|
[3] |
Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment-2017, Ahamd N, Ahuia SD, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet, 2018, 392(10150):821-834. doi: 10.1016/s0140-6736(18)31644-1.
doi: 10.1016/s0140-6736(18)31644-1
URL
|
[4] |
Olayanju O, Limberis J, Esmail A, et al. Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa. Eur Respir J, 2018, 51(5):1800544. doi: 10.1183/1399300.00544-2018.
doi: 10.1183/1399300.00544-2018
URL
|
[5] |
中国防痨协会. 耐药结核病化学治疗指南(2019年简版). 中国防痨杂志, 2019, 41(10):1025-1073. doi: 10.3969/j.issn.1000-6621.2019.10.001.
doi: 10.3969/j.issn.1000-6621.2019.10.001
|
[6] |
World Health Organization. The use of bedaquiline in the treatment of multidrug resistant tuberculosis. Geneva: World Health Organization, 2013.
|
[7] |
中华医学会结核病学分会, 抗结核新药贝达喹啉临床应用专家共识编写组. 抗结核新药贝达喹啉临床应用专家共识. 中华结核和呼吸杂志, 2018, 41(6):461-466. doi: 10.3760/cma.j.issn.1001-0939.2018.06.005.
doi: 10.3760/cma.j.issn.1001-0939.2018.06.005
|
[8] |
Haagsma AC, Podasca I, Koul A, et al. Probing the interaction of the diarylquinoline TMC207 with its target mycobacterial ATP synthase. PLoS One, 2011, 6(8):e23575. doi: 10.1371/journal.pone.0023575.
doi: 10.1371/journal.pone.0023575
URL
|
[9] |
Zhao Y, Fox T, Manning K, et al. Improved Treatment Outcomes With Bedaquiline When Substituted for Second-line Injectable Agents in Multidrug-resistant Tuberculosis: A Re-trospective Cohort Study. Clin Infet Dis, 2019, 68(9):1522-1529. doi: 10.1093/cid/ciy727.
doi: 10.1093/cid/ciy727
|
[10] |
吴国兰, 高静韬, 陈晓红, 等. 含贝达喹啉方案治疗耐多药/广泛耐药结核病的近期疗效及安全性分析. 中国防痨杂志, 2021, 43(9):899-904. doi: 10.3969/j.issn.1000-6621.2021.09.008.
doi: 10.3969/j.issn.1000-6621.2021.09.008
|
[11] |
Nunn AJ, Phillips PPJ, Meredith SK, et al. A trial of a shorter regimen for rifampin-resistant tuberculosis. N Engl J Med, 2019, 380(13):1201-1213. doi: 10.1056/NEJMoal1811867.
doi: 10.1056/NEJMoal1811867
URL
|
[12] |
Jones J, Mudaly V, Voget J, et al. Adverse drug reactions in South African patients receiving bedaquiline-containing tuberculosis treatment: an evaluation of spontaneously reported cases. BMC Infect Dis, 2019, 19(1):544. doi: 10.1186/s12879-019-4197-7.
doi: 10.1186/s12879-019-4197-7
URL
|
[13] |
Pym AS, Diacon AH, Tang SJ, et al. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. Eur Respir J, 2016, 47(2):564-574. doi: 10.1183/13993003.00724-2015.
doi: 10.1183/13993003.00724-2015
URL
|
[14] |
Mbuagbaw L, Guglielmetti L, Hewison C, et al. Outcomes of bedaquiline treatment in patients with multidrug-resistant tuberculosis. Emerg Infect Dis, 2019, 25(5):936-943. doi: 10.3201/eid2505.181823.
doi: 10.3201/eid2505.181823
URL
|
[15] |
Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med, 2009, 360(23):2397-2405. doi: 10.1056/NEJMoa0808427.
doi: 10.1056/NEJMoa0808427
URL
|
[16] |
Diacon AH, Donaid PR, Pym A, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother, 2012, 56(6):3271-3276. doi: 10.1128/AAC.06126-11.
doi: 10.1128/AAC.06126-11
pmid: 22391540
|
[17] |
Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science, 2005, 307(5707):223-237. doi: 10.1126/science.1106753.
doi: 10.1126/science.1106753
pmid: 15591164
|
[18] |
Gueta I, Klempfner R, Markovist N, et al. Clinically significant incidental QTc prolongation is subject to within-individual variability. Ann Noninvasive Electrocardiol, 2020, 25(2): el2699. doi: 10.1111/anec.12699.
doi: 10.1111/anec.12699
|
[19] |
Olayanju O, Esmail A, Limberis J, et al. A regimen containing bedaquiline and delamanid compared to bedaquiline in patients with drug-resistant tuberculosis. Eur Respir J, 2020, 55(1):1901181. doi: 10.1183/13993003.01181-2019.
doi: 10.1183/13993003.01181-2019
URL
|
[20] |
谢莉, 高静韬, 马丽萍, 等. 含贝达喹啉方案治疗耐多药肺结核对患者心电图QT间期的影响. 中国防痨杂志, 2020, 42(7):687-694. doi: 10.3969/j.issn.1000-6621.2020.07.009.
doi: 10.3969/j.issn.1000-6621.2020.07.009
|